GLP-1s for Obstructive Sleep Apnea (OSA): What to Know

Should You Take a GLP-1 Drug to Treat OSA?

Should You Take a GLP-1 Drug to Treat OSA?
Everyday Health
You likely know that GLP-1 drugs can help with everything from weight loss to type 2 diabetes, but now, one of these medications has been approved by the U.S. Food and Drug Administration for treating obstructive sleep apnea (OSA).

For some people, this drug, Zepbound (tirzepatide), could be part of a larger arsenal of tools for treating a condition linked to various health risks. “Untreated, obstructive sleep apnea is associated with an increased risk of heart attack and stroke; it’s also been associated with worsening of other medical conditions, such as diabetes and high blood pressure,” says Stephanie Ashraf, MD, a board-certified internal and sleep medicine specialist and assistant professor of clinical medicine at Indiana University School of Medicine in Indianapolis.

To treat OSA, which causes frequent night wakings, doctors may prescribe anything from a special mouthpiece that can help you breathe better to a CPAP machine that opens your airways with a steady stream of airflow.

They might also suggest weight loss, depending on what’s causing OSA.

“Weight loss can improve OSA by reducing fat around the upper airway and improving respiratory mechanics,” says Xinhang Tu, BM, a sleep medicine physician at University of Michigan Health who is board-certified in internal medicine, sleep medicine, and obesity medicine.
Doctors often recommend lifestyle changes like moving more and eating healthy foods to address obesity, which is common among people with OSA.

Emerging research shows Zepbound can help patients lose weight and improve OSA symptoms.

Here’s how this type of GLP-1 can help with OSA, who the medicine is and isn’t for, and why your doctor might want to prescribe it in tandem with other treatments.

Questions to Ask Your Doctor

Thinking about whether a GLP-1 is right for you to help treat your OSA? Here are the questions to ask your physician.

  • Am I a good candidate to take Zepbound for OSA?
  • What health conditions would disqualify me from taking Zepbound for OSA?
  • How much weight would I need to lose to see an improvement in my nighttime breathing and daytime sleepiness?
  • How long would I need to take Zepbound before I start noticing improvements with OSA?
  • What are some side effects I might experience when taking Zepbound for OSA?
  • How is Zepbound different from other standard OSA treatments?
  • Would I be able to stop using a CPAP if my OSA symptoms get better with Zepbound?
  • How will you keep track of whether my OSA symptoms are improving with Zepbound?
  • Could Zepbound improve other aspects of my health, in addition to improving my OSA?

‘I Have OSA — Could I Benefit From Taking a GLP-1?’

While Zepbound has been shown to help people with OSA, this injectable medication specifically works for only a certain group of patients.

May Be a Good Fit For

  • Adults who have been clinically diagnosed with moderate to severe OSA who have obesity

  • Adults who have excess weight (overweight) and moderate to severe OSA, depending on the insurance
  • Adults with moderate to severe OSA and obesity who have a hard time using the CPAP machine (For example, some people may have trouble falling asleep with a mask, while others might feel claustrophobic wearing the device.)

  • Adults with moderate to severe OSA who have additional diseases or conditions associated with obesity, such as high blood pressure and type 2 diabetes, where a tirzepatide could also provide other benefits

May Not Be a Good Fit For

  • Adults with mild OSA, as it has not been approved for this group

  • Adults who have structural issues that may be causing OSA, such as a small jaw or enlarged tonsils

  • Adults who are taking certain diabetes medications or birth control because the dosage may need to be adjusted while using this type of GLP-1 (Always discuss it with your doctor.)

Not a Good Fit For

  • People under 18 who have OSA, as children are not approved to take Zepbound (the only FDA-approved GLP-1 for OSA)

  • Adults who are pregnant, planning to become pregnant, or breastfeeding, which Zepbound is not approved for

  • Adults who have a history of pancreatitis or a condition that might increase their risk of developing medullary thyroid carcinoma, a very rare thyroid cancer

  • Patients with severe stomach or intestinal problems or active gallbladder disease

How GLP-1 Drugs Can Help With OSA

Doctors grade sleep apnea severity based on the number of times per hour someone has an abnormal breathing event, says Dr. Ashraf, and this is called the apnea-hypopnea index, or AHI. Moderate OSA is 15 or more abnormal events per hour, while severe OSA is considered 30 or more events per hour.

In clinical trials, tirzepatide produced substantial weight loss and reduced AHI by approximately 25 to 29 events per hour over one year, says Dr. Tu, and there was greater improvement in those who used a CPAP at the same time.

Zepbound is a dual receptor agonist, meaning it works on two hormonal pathways: GLP-1 and GIP, says Ashraf. By mimicking these two gut hormones, it slows how your stomach empties, stimulates fullness, and leads to weight loss.

“This combination has been associated with a greater percentage of weight reduction compared to other GLP-1 medications,” she adds.

 Weight loss can help improve OSA in someone with obesity because fat tissue around the throat, tongue, and the abdomen can increase the risk of airway collapse and reduce lung capacity during rest.

“Studies have consistently shown that a 10-percent weight reduction can significantly reduce the AHI,” says Ashraf.

 Also, in the studies that looked specifically at tirzepatide for OSA treatment, 40 to 50 percent of people treated with tirzepatide had improvement in sleep apnea to a level that may not require any other therapy, says Tu.

“We have known for years that with substantial weight loss following surgical intervention, such as the gastric sleeve or gastric bypass surgery, that patients have improvement and sometimes resolution of their OSA,” Ashraf says. “These medications offer a pathway without surgery to have clinically meaningful reduction in sleep apnea severity, and in some cases, they may resolve the OSA entirely,” Ashraf adds.

Are GLP-1 Drugs a Replacement for Other OSA Treatments?

Despite the clear benefits of Zepbound for OSA, this GLP-1 drug isn’t a replacement for conventional OSA treatment, including the CPAP machine. “I think of these treatments as addressing different aspects of OSA,” says Tu. For example, a CPAP machine can help you have better sleep right away (thanks to helping keep your airways open, which allows you to breathe freely). However, a patient on a tirzepatide may need 6 to 12 months on the medication before doctors see meaningful improvement in OSA severity, says Ashraf.

“Sleepiness symptoms and sleep disruption will improve faster with starting a CPAP than with weight loss, so I usually recommend patients start CPAP first or CPAP with tirzepatide,” says Ashraf. “But if a patient is very hesitant to start CPAP, we can start with focusing on weight reduction first,” says Ashraf. Also, reassessment is key. “After significant weight loss, repeat sleep testing can help determine whether OSA severity or PAP requirements have changed,” says Tu.

Just know: In the same studies that looked at taking a tirzepatide for OSA treatment, notably 50 percent or more still had sleep apnea severe enough to require other treatment, such as ongoing CPAP or other therapy, explains Ashraf.

Some people still may not be a perfect fit for Zepbound. In addition to people who can’t take the medicine (due to a family history of a certain type of thyroid cancer, for example), some may not be able to tolerate the side effects, such as nausea and constipation.

 Still, lifestyle interventions — including supplementation, getting enough protein, staying hydrated, and eating smaller meals — can help mitigate side effects.

“Oftentimes, side effects improve after a couple of weeks, but if they do not, I recommend stopping the medication,” says Ashraf.

Finally, using Zepbound is not a quick fix for OSA. “It is also important to know there is a high likelihood that weight will return if the medication is stopped, even after dietary and lifestyle changes have been implemented,” says Ashraf. “I advise patients that we expect them to be taking this medication or another similar medication possibly for the rest of their life,” Ashraf adds.

EDITORIAL SOURCES
Everyday Health follows strict sourcing guidelines to ensure the accuracy of its content, outlined in our editorial policy. We use only trustworthy sources, including peer-reviewed studies, board-certified medical experts, patients with lived experience, and information from top institutions.
Resources
  1. FDA Approves First Medication for Obstructive Sleep Apnea. U.S. Food and Drug Administration. December 20, 2024.
  2. Obstructive Sleep Apnea. Cleveland Clinic. December 4, 2024.
  3. Oral Appliance Therapy. American Academy of Dental Sleep Medicine.
  4. Continuous Positive Airway Pressure (CPAP). Mayo Clinic.
  5. Esmaeili N et al. The Relationship Between Obesity and Obstructive Sleep Apnea in Four Community-Based Cohorts: An Individual Participant Data Meta-Analysis of 12,860 Adults. eClinicalMedicine. May 2025.
  6. St-Onge MP et al. Weight Loss Is Integral to Obstructive Sleep Apnea Management. Ten-Year Follow-Up in Sleep AHEAD. American Journal of Respiratory and Critical Care Medicine. January 15, 2021.
  7. Dandamudi M et al. Efficacy of GLP-1 Receptor Agonists in Treating Obstructive Sleep Apnea: A Systematic Review and Meta-Analysis of Cardiometabolic and Respiratory Outcomes. Sleep and Breathing. April 24, 2026.
  8. CPAP Machines: Tips for Avoiding 10 Common Problems. Mayo Clinic. January 21, 2026.
  9. Consequences of Obesity. Centers for Disease Control and Prevention. July 9, 2026.
  10. Zepbound (Tirzepatide) Injection. U.S. Food and Drug Administration. January 2026.
  11. Obstructive Sleep Apnea. Zepbound. 2026.
  12. Understanding the Results. Harvard Medical School. April 16, 2021.
  13. Malhotra A et al. Tirzepatide for the Treatment of Obstructive Sleep Apnea and Obesity. The New England Journal of Medicine. June 21, 2024.
  14. McCrimmon KK. What Is Zepbound? Does This Weight-Loss Drug Work Better Than Wegovy and Ozempic? UCHealth. May 18, 2026.
  15. Jiang Y et al. Why Does GLP-1 Agonist Combined With GIP and/or GCG Agonist Have Greater Weight Loss Effect Than GLP-1 Agonist Alone in Obese Adults Without Type 2 Diabetes? Diabetes, Obesity and Metabolism. March 2025.
  16. Lilly’s Tirzepatide Reduced Obstructive Sleep Apnea (OSA) Severity, With Up to 51.5% of Participants Meeting the Criteria for Disease Resolution. Lilly. June 21, 2024.
  17. Nutritional Priorities to Support GLP‐1 Therapy for Obesity: A Joint Advisory From the American College of Lifestyle Medicine, the American Society for Nutrition, the Obesity Medicine Association, and The Obesity Society. Obesity. August 2025.
Abhinav Singh

Abhinav Singh, MD

Medical Reviewer

Abhinav Singh, MD, is a board-certified sleep medicine specialist and the medical director of the Indiana Sleep Center. He is also an associate clinical professor at Marian Univers...

Leslie Barrie

Author
Leslie Barrie is a health and nutrition writer and editor who loves running marathons and attempting to cook healthy meals for her family (even if they don’t always turn out as pla...